Core Insights - Guardian Pharmacy Services reported strong financial performance for 2025, with adjusted EBITDA increasing by 27% year over year and margins expanding to 7.9% despite challenges from acquisitions and market conditions [1][5][10] - The company achieved organic revenue growth of 13%, attributed to new resident additions and increased script volumes, with total reported revenue growth of 18% for the year [2][5] - Management raised the 2026 adjusted EBITDA guidance to $120–$124 million while maintaining revenue guidance of $1.40–$1.42 billion, anticipating to offset pricing impacts from the Inflation Reduction Act [3][5][15] Financial Performance - Adjusted EBITDA for 2025 was reported at $115 million, with a significant increase in Q4 adjusted EBITDA by 53% to $39.5 million [5][10] - The company’s cash balance rose to approximately $66 million, up from $36 million at the end of Q3 2025, indicating strong cash flow generation [11] - Gross profit for Q4 increased by 27% to $85.5 million, with gross margin expanding to 21.5% from 19.8% a year earlier [6][10] Operational Highlights - Guardian served over 205,000 residents, marking a 10% increase year over year, with Q4 script volumes growing by 14% [4][6] - The company completed four acquisitions and continued investments in greenfield startups, funded by strong cash flow [4][11][12] - Vaccine clinics administered over 120,000 vaccines in Q3 and Q4, contributing to improved profitability and operational metrics [7][10] Strategic Outlook - Management noted the operational complexity due to the implementation of the Inflation Reduction Act and its potential impact on pricing and reimbursement dynamics [13][14] - The company is actively monitoring industry conditions, including facility-level consolidation and demographic trends, to identify market opportunities [14] - Future revenue impacts from additional branded drug negotiations under the IRA are expected to be smaller than those anticipated for 2026, with an estimated $65 million revenue headwind in 2027 [17]